Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

NCT01200485 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Leukemia
Lymphoma

Interventions

DRUG: Rasburicase
DRUG: Allopurinol

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]